PT3393505T - Vacinas do zika recombinantes - Google Patents
Vacinas do zika recombinantesInfo
- Publication number
- PT3393505T PT3393505T PT168267383T PT16826738T PT3393505T PT 3393505 T PT3393505 T PT 3393505T PT 168267383 T PT168267383 T PT 168267383T PT 16826738 T PT16826738 T PT 16826738T PT 3393505 T PT3393505 T PT 3393505T
- Authority
- PT
- Portugal
- Prior art keywords
- recombinant zika
- zika vaccines
- vaccines
- recombinant
- zika
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/282—Porous sorbents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202480.8A EP3184119A1 (en) | 2015-12-23 | 2015-12-23 | Chromatography based purification strategies for measles scaffold based viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3393505T true PT3393505T (pt) | 2021-04-28 |
Family
ID=55027478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT168267383T PT3393505T (pt) | 2015-12-23 | 2016-12-23 | Vacinas do zika recombinantes |
Country Status (17)
Country | Link |
---|---|
US (2) | US11110162B2 (el) |
EP (5) | EP3184119A1 (el) |
BR (1) | BR112018012962A2 (el) |
CY (1) | CY1124202T1 (el) |
DK (1) | DK3393505T3 (el) |
ES (1) | ES2867954T3 (el) |
HR (1) | HRP20210591T1 (el) |
HU (1) | HUE054847T2 (el) |
LT (1) | LT3393505T (el) |
MX (1) | MX2018007860A (el) |
PL (1) | PL3393505T3 (el) |
PT (1) | PT3393505T (el) |
RS (1) | RS61939B1 (el) |
SG (2) | SG10202004516VA (el) |
SI (1) | SI3393505T1 (el) |
WO (2) | WO2017109222A1 (el) |
ZA (2) | ZA201804071B (el) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
EP3468590A1 (en) | 2016-06-13 | 2019-04-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays |
US11020473B2 (en) * | 2016-06-24 | 2021-06-01 | Institut Pasteur | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases |
WO2018022790A1 (en) * | 2016-07-27 | 2018-02-01 | Hawaii Biotech Inc. | Optimized zika virus envelope gene and expression thereof |
GB201613191D0 (en) * | 2016-07-29 | 2016-09-14 | Univ Oxford Innovation Ltd | Zika virus vaccine |
BR112019000872A2 (pt) | 2016-08-16 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | métodos para quantificar anticorpos individuais de uma mistura |
CA3039788A1 (en) | 2016-10-25 | 2018-05-03 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
EP3412307A1 (en) * | 2017-06-07 | 2018-12-12 | Institut Pasteur | Recombinant measles virus expressing zika virus proteins and their applications |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
WO2019060062A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals Inc. | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM |
WO2019090233A2 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Method for inactivating zika virus and for determining the completeness of inactivation |
KR20200090893A (ko) | 2017-11-30 | 2020-07-29 | 다케다 백신즈 인코포레이티드 | 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들 |
CN107987136A (zh) * | 2017-12-13 | 2018-05-04 | 清华大学 | Zikv-ns1蛋白及其在制备寨卡病毒传播阻断疫苗中的应用 |
WO2019204654A1 (en) * | 2018-04-18 | 2019-10-24 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
EP3581646A1 (en) | 2018-06-15 | 2019-12-18 | Themis Bioscience GmbH | Integrated manufacturing and chromatographic system for virus production |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
WO2020081759A1 (en) * | 2018-10-17 | 2020-04-23 | Texas Tech University System | Multivalent virus like particle vaccines |
KR101966841B1 (ko) | 2018-12-12 | 2019-04-08 | 대한민국 | 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도 |
EP3673917A1 (en) * | 2018-12-28 | 2020-07-01 | Themis Bioscience GmbH | Norovirus vaccines |
CN109943536B (zh) * | 2019-03-26 | 2021-09-14 | 昆明理工大学 | 一种戊型肝炎病毒的培养方法及其灭活疫苗的制备方法 |
WO2020236874A1 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Zika virus constructs and therapeutic compositions thereof |
US20230065376A1 (en) * | 2020-02-05 | 2023-03-02 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
CN111875680A (zh) * | 2020-08-08 | 2020-11-03 | 武汉圣润生物科技有限公司 | 一种预防新型冠状病毒微颗粒的制备方法及应用 |
EP3957650A1 (en) | 2020-08-17 | 2022-02-23 | Themis Bioscience GmbH | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation |
CN113322282A (zh) * | 2021-04-20 | 2021-08-31 | 华南农业大学 | 稳定表达NS1蛋白的犬肾细胞系MDCK-pCDH-NS1及其构建方法和应用 |
WO2023250054A1 (en) * | 2022-06-23 | 2023-12-28 | Merck Sharp & Dohme Llc | Immunogenic compositions for epstein-barr virus proteins |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0210907A (pt) | 2001-06-01 | 2004-12-21 | Acambis Inc | Vetores de flavivìrus quiméricos |
DE60233038D1 (de) | 2002-06-20 | 2009-09-03 | Pasteur Institut | Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen |
CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
AU2006270225A1 (en) * | 2005-07-14 | 2007-01-25 | Mayo Foundation For Medical Education And Research | Paramyxoviridae virus preparations |
PL2301572T3 (pl) * | 2005-11-01 | 2015-02-27 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego |
DK1939214T3 (da) | 2006-12-22 | 2013-10-14 | Pasteur Institut | Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira |
EP3269728B1 (en) * | 2011-10-20 | 2020-12-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
SG11201403010TA (en) * | 2011-12-09 | 2014-07-30 | Pasteur Institut | Multiplex immuno screening assay |
EP2712871A1 (en) | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
US9267114B2 (en) | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
WO2016130786A2 (en) * | 2015-02-15 | 2016-08-18 | Integral Molecular, Inc. | Flaviviridae proteins and virions and methods of use thereof |
WO2016145149A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
-
2015
- 2015-12-23 EP EP15202480.8A patent/EP3184119A1/en not_active Withdrawn
-
2016
- 2016-03-29 EP EP16162688.2A patent/EP3184118B1/en active Active
- 2016-12-23 DK DK16826738.3T patent/DK3393505T3/da active
- 2016-12-23 PL PL16826738T patent/PL3393505T3/pl unknown
- 2016-12-23 MX MX2018007860A patent/MX2018007860A/es unknown
- 2016-12-23 SG SG10202004516VA patent/SG10202004516VA/en unknown
- 2016-12-23 SI SI201631217T patent/SI3393505T1/sl unknown
- 2016-12-23 EP EP16826738.3A patent/EP3393505B1/en active Active
- 2016-12-23 ES ES16826738T patent/ES2867954T3/es active Active
- 2016-12-23 SG SG11201804496UA patent/SG11201804496UA/en unknown
- 2016-12-23 RS RS20210601A patent/RS61939B1/sr unknown
- 2016-12-23 LT LTEP16826738.3T patent/LT3393505T/lt unknown
- 2016-12-23 BR BR112018012962A patent/BR112018012962A2/pt active Search and Examination
- 2016-12-23 EP EP16828744.9A patent/EP3393513B1/en active Active
- 2016-12-23 US US16/063,239 patent/US11110162B2/en active Active
- 2016-12-23 HU HUE16826738A patent/HUE054847T2/hu unknown
- 2016-12-23 US US16/063,240 patent/US10894079B2/en active Active
- 2016-12-23 WO PCT/EP2016/082659 patent/WO2017109222A1/en active Application Filing
- 2016-12-23 EP EP21165273.0A patent/EP3903814A1/en active Pending
- 2016-12-23 PT PT168267383T patent/PT3393505T/pt unknown
- 2016-12-23 WO PCT/EP2016/082628 patent/WO2017109211A1/en active Application Filing
-
2018
- 2018-06-18 ZA ZA2018/04071A patent/ZA201804071B/en unknown
- 2018-07-16 ZA ZA2018/04735A patent/ZA201804735B/en unknown
-
2021
- 2021-04-13 HR HRP20210591TT patent/HRP20210591T1/hr unknown
- 2021-05-26 CY CY20211100454T patent/CY1124202T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL3393505T3 (pl) | 2021-10-25 |
MX2018007860A (es) | 2018-11-09 |
US20190083601A1 (en) | 2019-03-21 |
EP3184118B1 (en) | 2020-05-06 |
EP3393505A1 (en) | 2018-10-31 |
ES2867954T3 (es) | 2021-10-21 |
WO2017109211A1 (en) | 2017-06-29 |
US10894079B2 (en) | 2021-01-19 |
SG11201804496UA (en) | 2018-07-30 |
BR112018012962A2 (pt) | 2018-12-04 |
US11110162B2 (en) | 2021-09-07 |
SI3393505T1 (sl) | 2021-08-31 |
US20180371426A1 (en) | 2018-12-27 |
SG10202004516VA (en) | 2020-06-29 |
ZA201804071B (en) | 2020-01-29 |
WO2017109211A9 (en) | 2017-07-20 |
EP3184119A1 (en) | 2017-06-28 |
EP3393513A1 (en) | 2018-10-31 |
EP3393513B1 (en) | 2021-04-21 |
EP3184118A1 (en) | 2017-06-28 |
ZA201804735B (en) | 2019-05-29 |
DK3393505T3 (da) | 2021-05-10 |
CY1124202T1 (el) | 2022-05-27 |
EP3903814A1 (en) | 2021-11-03 |
LT3393505T (lt) | 2021-05-25 |
HRP20210591T1 (hr) | 2021-05-28 |
RS61939B1 (sr) | 2021-07-30 |
EP3393505B1 (en) | 2021-03-31 |
HUE054847T2 (hu) | 2021-10-28 |
WO2017109222A1 (en) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201804071B (en) | Recombinant zika vaccines | |
HUE061679T2 (hu) | Zika vírus vakcina | |
SG10201913630YA (en) | Zika virus vaccine | |
HK1246183A1 (zh) | Hpv疫苗 | |
IL268920A (en) | Peptide components | |
ZA201701851B (en) | Fmdv recombinant vaccines and uses thereof | |
ZA201702891B (en) | Interferon alpha 2b variants | |
PL3207053T3 (pl) | Nowe peptydy immunogenne | |
GB201518684D0 (en) | Vaccine | |
GB201410971D0 (en) | Vaccine | |
GB201613191D0 (en) | Zika virus vaccine | |
IL281197B (en) | Formulations of factor ix that have been lyophilized | |
GB201522132D0 (en) | Vaccine | |
GB201506041D0 (en) | Avian vaccine | |
PL3322718T3 (pl) | Histonowe szczepionki przeciwnowotworowe | |
GB201508099D0 (en) | Dengue vaccines | |
GB201608821D0 (en) | Vaccines | |
LT3188755T (lt) | Vakcina | |
GB201504579D0 (en) | Ovine vaccine | |
GB201417214D0 (en) | Vaccine | |
PT3393510T (pt) | Vacina contra o vírus zika | |
GB201704892D0 (en) | Improved vaccines | |
GB201614387D0 (en) | Improved vaccines | |
GB201518917D0 (en) | Vaccination | |
GB201521608D0 (en) | Vaccine composition |